Equillium (EQ) Interest Expenses (2018 - 2023)
Equillium (EQ) posted quarterly Interest Expenses of $10.6 million for Q1 2026, up 10989.58% year-over-year from N/an in Q1 2025, and up 27197.44% quarter-over-quarter from $39000.0 in Q4 2025.
Powered by 
Analysis
Equillium (EQ) Interest Expenses (2018 - 2023) Analysis & Trends
Equillium (EQ) has reported Interest Expenses for 10 consecutive years, with $10.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Interest Expenses rose 10989.58% year-over-year to $10.6 million; the TTM figure through Mar 2026 stood at $10.6 million (up 1075.06% YoY), while the FY2025 annual figure was $54.7 million, up 7.4% from the prior year.
- Interest Expenses advanced to $10.6 million in Q1 2026 per EQ's latest filing, from $39000.0 in the prior quarter.
- Across five years, Interest Expenses topped out at $13.6 million in Q1 2024 and bottomed at $39000.0 in Q4 2025.
- Historically, Interest Expenses has averaged $2.1 million across 5 years, with a median of $276500.0 in 2022.
- Annual changes were most pronounced in 2025 — Interest Expenses slumped 99.29% — and 2026, when it surged 10989.58%.
- Equillium's Interest Expenses stood at $65000.0 in 2022, then surged by 600.0% to $455000.0 in 2023, then plunged by 72.97% to $123000.0 in 2024, then plunged by 68.29% to $39000.0 in 2025, then surged by 27197.44% to $10.6 million in 2026.
- Business Quant data shows EQ's Interest Expenses at $10.6 million in Q1 2026, $39000.0 in Q4 2025, and $4.4 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 11.00 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | -1.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 23.78 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 39.74 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 82.05 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 93.62 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 20.27 Mn |
| 10 | Equillium | 249.33 Mn | 249.33 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2023 | 259,000.00 |
| Mar 31, 2023 | 232,000.00 |
| Dec 31, 2022 | 271,000.00 |
| Sep 30, 2022 | 267,000.00 |
| Jun 30, 2022 | 259,000.00 |
| Mar 31, 2022 | 255,000.00 |
| Dec 31, 2021 | 266,000.00 |
| Sep 30, 2021 | 266,000.00 |
| Jun 30, 2021 | 270,000.00 |
| Mar 31, 2021 | 271,000.00 |
| Dec 31, 2020 | 276,000.00 |
| Sep 30, 2020 | 276,000.00 |
| Jun 30, 2020 | 274,000.00 |
| Mar 31, 2020 | 273,000.00 |
| Dec 31, 2019 | 277,000.00 |
| Sep 30, 2019 | 2,000.00 |
| Dec 31, 2018 | 229,000.00 |
| Sep 30, 2018 | 1.22 Mn |
| Jun 30, 2018 | 619,000.00 |
| Mar 31, 2018 | 489,000.00 |